Format

Send to

Choose Destination
Oncotarget. 2017 Jun 1;8(40):68769-68779. doi: 10.18632/oncotarget.18332. eCollection 2017 Sep 15.

A cerebrospinal fluid microRNA signature as biomarker for glioblastoma.

Author information

1
Center for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
2
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
3
Biostatistics Department, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
4
Department of Neurosurgery, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
5
Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
6
Department of Neurological Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
7
Department of Neurosciences, University of California, San Diego, CA, USA.
8
State Key Laboratory of Medical Neurobiology, Institutes of Brain Science, The Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China.

Abstract

PURPOSE:

To develop a cerebrospinal fluid (CSF) miRNA diagnostic biomarker for glioblastoma.

EXPERIMENTAL DESIGN:

Glioblastoma tissue and matched CSF from the same patient (obtained prior to tumor manipulation) were profiled by TaqMan OpenArray® Human MicroRNA Panel. CSF miRNA profiles from glioblastoma patients and controls were created from three discovery cohorts and confirmed in two validation cohorts.

RESULTS:

miRNA profiles from clinical CSF correlated with those found in glioblastoma tissues. Comparison of CSF miRNA profiles between glioblastoma patients and non-brain tumor patients yielded a tumor "signature" consisting of nine miRNAs. The "signature" correlated with glioblastoma tumor volume (p=0.008). When prospectively applied to cisternal CSF, the sensitivity and specificity of the 'signature' for glioblastoma detection were 67% and 80%, respectively. For lumbar CSF, the sensitivity and specificity of the signature were 28% and 95%, respectively. Comparable results were obtained from analyses of CSF extracellular vesicles (EVs) and crude CSF.

CONCLUSION:

We report a CSF miRNA signature as a "liquid biopsy" diagnostic platform for glioblastoma.

KEYWORDS:

CSF; extracellular vesicle; liquid biopsy

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center